Antibiotic Incentives: Prize Fund Is Focus Of Presidential Report On Incentives
Upcoming White House report on antibiotic incentives will provide a strong endorsement of one-time payments to reward successful development of new therapeutics. That is a mixed blessing for advocates for legislative action for incentives who are focusing on 'wildcard' patents.
You may also be interested in...
Antibiotic Development: HHS Not Yet Sold On ‘Pull’ Incentives
As HHS develops strategic framework to combat antibiotic resistance, post-market financial incentives may not be included, despite prominent government panels recommending the idea years ago and GAO urging the department to do so in a just-released report. Stakeholders told that GAO reimbursement reform won't be enough to spur a strong antibiotic pipeline.
New Report Calls For Pushing And Pulling In Global Fight Against Superbugs
New DRIVE-AB report on revitalizing antibiotic R&D suggests market-entry rewards of up to $1bn for companies introducing novel products, cites need for increasing public funding of R&D support.
Doubling Down On Antibiotic Incentives: Congress, Obama Administration Drafting Proposals
The 2012 FDA Safety & Innovation Act included important new incentives for antibiotic developers. But the Obama Administration and key legislators want to do even more to revive R&D in the space. What will it take to bring Big Pharma back?